for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PetIQ Inc

PETQ.OQ

Latest Trade

34.76USD

Change

-0.18(-0.52%)

Volume

132,985

Today's Range

34.25

 - 

35.43

52 Week Range

21.28

 - 

36.33

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
34.94
Open
34.81
Volume
132,985
3M AVG Volume
5.56
Today's High
35.43
Today's Low
34.25
52 Week High
36.33
52 Week Low
21.28
Shares Out (MIL)
28.27
Market Cap (MIL)
982.75
Forward P/E
--
Dividend (Yield %)
--

Next Event

PetIQ Inc at Bank of America Merrill Lynch Animal Health Summit

Latest Developments

More

Petiq, Inc. Provides Update On Wellness Center Openings

PetIQ Agrees To Acquire Capstar Products From Elanco

PetIQ Reiterates Full Year 2019 Outlook

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PetIQ Inc

PetIQ, Inc. is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield. It distributes the products through veterinarian, retail and e-commerce channels. The Company offers its products in a range of categories, including Rx Medications, OTC Medications and Supplies, and Health and Wellness Products. Rx Medications offering includes heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics and other specialty medications. The Company manufactures Heart Shield Plus, version of Heartgard Plus, which prevents heartworm infection in dogs. The Company also manufactures TruProfen, the version of Rimadyl, which treats arthritis in dogs. OTC Medications and Supplies include flea and tick control products.

Contact Info

923 S Bridgeway Pl

+1.208.9398900

https://petiq.com/

Executive Leadership

McCord Christensen

Chairman of the Board, Chief Executive Officer

Susan Sholtis

President

John Newland

Chief Financial Officer

Michael A Smith

Executive Vice President, Products

Lauren Olavessen

Senior Vice President, Chief Medical Officer

Key Stats

1.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

0.5K

2019(E)

0.7K
EPS (USD)

2017

1.280

2018

0.770

2019(E)

1.193
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.48
Price To Book (MRQ)
3.43
Price To Cash Flow (TTM)
112.48
Total Debt To Equity (MRQ)
90.87
LT Debt To Equity (MRQ)
89.65
Return on Investment (TTM)
-1.34
Return on Equity (TTM)
-1.06

Latest News

Latest News

BRIEF-PetIQ, Inc. Enters Into Definitive Agreement To Acquire VIP Petcare

* PETIQ INC - ACQUISITION ANTICIPATED TO GENERATE APPROXIMATELY $450 MILLION TO $500 MILLION IN COMBINED COMPANY PRO FORMA 2018 NET SALES

BRIEF-Park West Asset Management LLC Reports 5.5 Percent Passive Stake In Petiq Inc

* PARK WEST ASSET MANAGEMENT LLC REPORTS 5.5 PERCENT PASSIVE STAKE IN PETIQ INC AS OF NOVEMBER 28 - SEC FILING Source text: (http://bit.ly/2nHqoDX) Further company coverage:

BRIEF-Petiq Q2 sales up 42.3 pct to $87.2 mln

* Petiq Inc reports second quarter fiscal 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up